Status:
WITHDRAWN
Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)
Lead Sponsor:
Gangnam Severance Hospital
Conditions:
Contact Person From COVID-19 Confirmed Patient
Eligibility:
All Genders
18-99 years
Phase:
PHASE3
Brief Summary
There is no known definite treatment after exposure to SARS-CoV-2, but the some animal and clinical trials confirmed the efficacy of hydroxychloroquine (HCQ) or chloroquine against SARS-CoV-2. Thus, i...
Eligibility Criteria
Inclusion
- A contact person from confirmed case of SARS-CoV-2 infection
- Medical staff exposed from confirmed case of SARS-CoV-2 infection in hospitals
- Persons exposed to SARS-CoV-2 in COVID-19 outbreak situation with certain workplaces, religious groups, and military, etc.
- Subjects of study include both symptomatic and asymptomatic contacts.
Exclusion
- Hypersensitivity to Chloroquine or Hydroxychloroquine
- Those who are contraindicated in Hydroxychloroquine administration according to the permission requirements such as pregnant women, nursing mothers, visual disorders, macular disease, and porphyria, etc.
- Human immunodeficiency virus (HIV) infected person
- Patients with autoimmune disease (Systemic lupus erythematosus, Mixed connective tissue disease)
- Patients with autoimmune rheumatoid inflammatory disease (AIIRD; Autoimmune inflammatory rheumatic diseases - Ankylosing spondylitis, Rheumatic arthritis, Psoriatic arthritis)
- Arrhythmia, liver cirrhosis of Child Pugh C, chronic renal failure with eGFR≤30mL / min / 1.73m2
- A person who is positive in the COVID-19 screening PCR test before starting PEP
Key Trial Info
Start Date :
April 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 29 2020
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04330144
Start Date
April 1 2020
End Date
June 29 2020
Last Update
August 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gangnam Severance Hospital
Seoul, South Korea